Adjuvant heparanase inhibitor PI-88 therapy for hepatocellular carcinoma recurrence

World Journal of Gastroenterology

Volumn 20, Issue 32, 2014, Pages 11381-11393

  Liu, Chun Jen ^a   Chang, Juliana ^a   Lee, Po Huang ^a   Lin, Deng Yn ^b   Wu, Cheng Chung ^c   Jeng, Long Bin ^d   Lin, Yih Jyh ^e   Mok, King Tong ^f   Lee, Wei Chen ^b   Yeh, Hong Zen ^c   Ho, Ming Chih ^a   Yang, Sheng Shun ^c   Yang, Mei Due ^d   Yu, Ming Chin ^b   Hu, Rey Heng ^a   Peng, Cheng Yuan ^d   Lai, Kuan Lang ^g   Chang, Stanley Shi Chung ^g   Chen, Pei Jer ^a  

^a NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^b CHANG GUNG UNIVERSITY   (Taiwan)

^c TAICHUNG VETERANS GENERAL HOSPITAL   (Taiwan)

^d CHINA MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^e NATIONAL CHENG KUNG UNIVERSITY HOSPITAL   (Taiwan)

^f KAOHSIUNG VETERANS GENERAL HOSPITAL   (Taiwan)

^g Medigen Biotechnology Corporation   (Taiwan)

Author keywords

Adjuvant therapy; Antiangiogenesis; Antimetastasis; Disease free survival; Heparanase inhibitor; Hepatocellular carcinoma; PI 88; Tumor recurrence

Indexed keywords

MUPARFOSTAT; ANTINEOPLASTIC AGENT; BETA GLUCURONIDASE; ENZYME INHIBITOR; HEPARANASE; OLIGOSACCHARIDE; PHOSPHOMANNOPENTAOSE SULFATE;

ADULT; AGED; AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; BLEEDING; CANCER ADJUVANT THERAPY; CANCER RECURRENCE; CONTROLLED STUDY; DISEASE FREE SURVIVAL; DRUG EFFICACY; DRUG SAFETY; FEMALE; FOLLOW UP; HEPATITIS B; HEPATITIS C; HUMAN; INJECTION SITE PAIN; LIVER CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; MULTIPLE CANCER; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; OVERALL SURVIVAL; PARTIAL THROMBOPLASTIN TIME; PATIENT COMPLIANCE; PHASE 2 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; RECURRENCE FREE SURVIVAL; ADJUVANT CHEMOTHERAPY; ANTAGONISTS AND INHIBITORS; CARCINOMA, HEPATOCELLULAR; CLINICAL TRIAL; DRUG ADMINISTRATION; ENZYMOLOGY; LIVER NEOPLASMS; METABOLISM; MIDDLE AGED; MORTALITY; MULTICENTER STUDY; PATHOLOGY; RISK FACTOR; SURVIVAL; TAIWAN; TIME; TREATMENT OUTCOME;

ADULT; AGED; ANTINEOPLASTIC AGENTS; CARCINOMA, HEPATOCELLULAR; CHEMOTHERAPY, ADJUVANT; DISEASE-FREE SURVIVAL; DRUG ADMINISTRATION SCHEDULE; ENZYME INHIBITORS; FEMALE; GLUCURONIDASE; HUMANS; LIVER NEOPLASMS; MALE; MIDDLE AGED; OLIGOSACCHARIDES; RISK FACTORS; SURVIVAL ANALYSIS; TAIWAN; TIME FACTORS; TREATMENT OUTCOME;

EID: 84909630780     PISSN: 10079327     EISSN: 22192840     Source Type: Journal    
DOI: 10.3748/wjg.v20.i32.11384     Document Type: Article

References (20)

1. Faloppi L, Scartozzi M, Maccaroni E, Di Pietro Paolo M, Berardi R, Del Prete M, Cascinu S. Evolving strategies for the treatment of hepatocellular carcinoma: from clinical-guided to molecularly-tailored therapeutic options. Cancer Treat Rev 2011; 37: 169-177 [PMID: 20800360 DOI: 10.1016/j.ctrv.2010.08.001]
2. Llovet JM, Burroughs A, Bruix J. Hepatocellular carcinoma. Lancet 2003; 362: 1907-1917 [PMID: 14667750]
3. Ye SL, Takayama T, Geschwind J, Marrero JA, Bronowicki JP. Current approaches to the treatment of early hepatocellular carcinoma. Oncologist 2010; 15 Suppl 4: 34-41 [PMID: 21115579 DOI: 10.1634/theoncologist]
4. Poon RT. Prevention of recurrence after resection of hepatocellular carcinoma: a daunting challenge. Hepatology 2011; 54: 757-759 [PMID: 21793027 DOI: 10.1002/hep.24569]
5. Tung-Ping Poon R, Fan ST, Wong J. Risk factors, prevention, and management of postoperative recurrence after resection of hepatocellular carcinoma. Ann Surg 2000; 232: 10-24 [PMID: 10862190]
6. Ishii H, Yamamoto J, Ikari T. Adjuvant treatments for resectable hepatocellular carcinoma. J Hepatobiliary Pancreat Surg 2008; 15: 459-462 [PMID: 18836796 DOI: 10.1007/s00534-008-1359-1]
7. Schwartz JD, Schwartz M, Mandeli J, Sung M. Neoadjuvant and adjuvant therapy for resectable hepatocellular carcinoma: review of the randomised clinical trials. Lancet Oncol 2002; 3: 593-603 [PMID: 12372721]
8. Llovet JM, Di Bisceglie AM, Bruix J, Kramer BS, Lencioni R, Zhu AX, Sherman M, Schwartz M, Lotze M, Talwalkar J, Gores GJ. Design and endpoints of clinical trials in hepatocellular carcinoma. J Natl Cancer Inst 2008; 100: 698-711 [PMID: 18477802 DOI: 10.1093/jnci/djn134]
9. Kudchadkar R, Gonzalez R, Lewis KD. PI-88: a novel inhibitor of angiogenesis. Expert Opin Investig Drugs 2008; 17: 1769-1776 [PMID: 18922112 DOI: 10.1517/13543784.17.11.1769]
10. Joyce JA, Freeman C, Meyer-Morse N, Parish CR, Hanahan D. A functional heparan sulfate mimetic implicates both heparanase and heparan sulfate in tumor angiogenesis and invasion in a mouse model of multistage cancer. Oncogene 2005; 24: 4037-4051 [PMID: 15806157]
11. Cochran S, Li C, Fairweather JK, Kett WC, Coombe DR, Ferro V. Probing the interactions of phosphosulfomannans with angiogenic growth factors by surface plasmon resonance. J Med Chem 2003; 46: 4601-4608 [PMID: 14521421]
12. Parish CR, Freeman C, Brown KJ, Francis DJ, Cowden WB. Identification of sulfated oligosaccharide-based inhibitors of tumor growth and metastasis using novel in vitro assays for angiogenesis and heparanase activity. Cancer Res 1999; 59: 3433-3441 [PMID: 10416607]
13. Liu CJ, Lee PH, Lin DY, Wu CC, Jeng LB, Lin PW, Mok KT, Lee WC, Yeh HZ, Ho MC, Yang SS, Lee CC, Yu MC, Hu RH, Peng CY, Lai KL, Chang SS, Chen PJ. Heparanase inhibitor PI-88 as adjuvant therapy for hepatocellular carcinoma after curative resection: a randomized phase II trial for safety and optimal dosage. J Hepatol 2009; 50: 958-968 [PMID: 19303160 DOI: 10.1016/j.jhep.2008.12.023]
14. Thall PF, Simon R, Ellenberg SS. Two-stage selection and testing designs for comparative clinical trials. Biometrika 1988; 75: 303-310
15. Forner A, Roayaie S. Clinical research in hepatocellular carcinoma: study design and endpoints. J Hepatol 2009; 50: 850-853 [PMID: 19329214 DOI: 10.1016/j.jhep.2009.02.016]
16. Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, de Oliveira AC, Santoro A, Raoul JL, Forner A, Schwartz M, Porta C, Zeuzem S, Bolondi L, Greten TF, Galle PR, Seitz JF, Borbath I, Häussinger D, Giannaris T, Shan M, Moscovici M, Voliotis D, Bruix J. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008; 359: 378-390 [PMID: 18650514 DOI: 10.1056/NEJMoa0708857]
17. Cheng AL, Kang YK, Chen Z, Tsao CJ, Qin S, Kim JS, Luo R, Feng J, Ye S, Yang TS, Xu J, Sun Y, Liang H, Liu J, Wang J, Tak WY, Pan H, Burock K, Zou J, Voliotis D, Guan Z. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol 2009; 10: 25-34 [PMID: 19095497]
18. Gedaly R, Angulo P, Hundley J, Daily MF, Chen C, Evers BM. PKI-587 and sorafenib targeting PI3K/AKT/mTOR and Ras/Raf/MAPK pathways synergistically inhibit HCC cell proliferation. J Surg Res 2012; 176: 542-548 [PMID: 22261591 DOI: 10.1016/j.jss.2011.10.045]
19. Fan ST, Mau Lo C, Poon RT, Yeung C, Leung Liu C, Yuen WK, Ming Lam C, Ng KK, Ching Chan S. Continuous improvement of survival outcomes of resection of hepatocellular carcinoma: a 20-year experience. Ann Surg 2011; 253: 745-758 [PMID: 21475015 DOI: 10.1097/SLA.0b013e3182111195]
20. Fan ST, Lo CM, Liu CL, Lam CM, Yuen WK, Yeung C, Wong J. Hepatectomy for hepatocellular carcinoma: toward zero hospital deaths. Ann Surg 1999; 229: 322-330 [PMID: 10077043]